Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antisoma hails success in ovarian cancer study
The trial showed a response rate of 75% for those treated with AS1404 plus chemotherapy compared with 63% for patients receiving chemotherapy alone. The addition of AS1404 to
The trial showed a response rate of 75% for those treated with AS1404 plus chemotherapy compared with 63% for patients receiving chemotherapy alone. The addition of AS1404 to
Results from the studies suggest that the company’s patented vaccine adjuvant known as Vaxfectin has the potential to be used as a dose-sparing agent with conventional flu vaccines
SC-1, developed by Debiopharm, is a fully human monoclonal IgM antibody that targets CD55SC-1, a cell surface receptor specifically expressed on gastric carcinoma cells. Under the terms of
The regulatory body also requested additional label language and clarification of already submitted data. Amgen submitted a biologics license supplement to the FDA for Aranesp in December 2005.
The two employees suspended are senior members in Bayer’s Global Drug Safety Group in Germany. Bayer also said that it has appointed an independent counsel to review the
With this approval, Aricept becomes the first and only prescription medication to treat the full spectrum of Alzheimer’s disease from mild, moderate to severe. Aricept, which is co-promoted
CAIV-T, a cold adapted influenza vaccine produced higher influenza serum antibody responses than an injectable trivalent inactivated flu vaccine (TIV). “These data are consistent with the results from
The application was supposed to be filed in the first quarter of 2007. The companies now plan to submit the new drug application in mid-2007. The companies said
The protocol was submitted to the FDA under the agency’s special protocol assessment (SPA) regulations. The SPA process allows for FDA evaluation of trial protocol that will form
Under the licensing agreement, Tracon will develop and manage clinical trials of Methoxyamine. Methoxyamine was developed by University Hospitals Case Medical Center researchers. Research for this new therapeutic